Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansoh Pharmaceutical Group CoHNSPF 91 Return-on-Tangible-Asset is 13.15% as of Dec. 2025, which is 10% below its 10-year median of 14.67. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.13 (Modestly Overvalued). Among 1,007 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 89.77% on this metric.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:
HNSPF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.65 Med: 14.67 Max: 31.44
Current: 15.88
During the past 10 years, Hansoh Pharmaceutical Group Co's highest Return-on-Tangible-Asset was 31.44%. The lowest was 8.65%. And the median was 14.67%.
HNSPF's Return-on-Tangible-Asset is ranked better than 89.77% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs HNSPF: 15.88
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms
Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Chart
HNSPF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 13.15% mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Return-on-Tangible-Asset of 13.15% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 10% below median its historical median of 14.67. Over the past decade, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset has ranged from 8.65 to 31.44. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #103 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 10.2%.
Is Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset too high?
Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Asset of 13.15% is 10% below median its 10-year median of 14.67. Over the past 10 years, this metric has ranged from a low of 8.65 to a high of 31.44. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Hansoh Pharmaceutical Group Co's value of 13.15% is 317.5% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #103 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #103 out of 1007 companies for Return-on-Tangible-Asset. This places Hansoh Pharmaceutical Group Co in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Hansoh Pharmaceutical Group Co's value of 13.15% is 317.5% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own Return-on-Tangible-Asset has ranged from 8.65 to 31.44 over the past decade. While the company's 10-year median is 14.67 vs. the industry median of 3.15, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Asset of 13.15% is 317.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Asset is 13.15%, which is 10% below median its own 10-year median of 14.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.13, compared to a current price of $3.83 — trading 22.2% above its estimated fair value. The current Return-on-Tangible-Asset is 13.15%, which is 10% below median its 10-year median of 14.67 and 317.5% above the Drug Manufacturers industry median of 3.15. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Return-on-Tangible-Asset is 13.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 22.2% above its estimated GF Value™ of $3.13.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
Return-on-Tangible-Asset: 13.15% (10% below median its 10-year median of 14.67)
GF Value™: $3.13 vs. price of $3.83 (22.2% above fair value)
Industry Position: 317.5% above the Drug Manufacturers median (#103 of 1007)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score
Get the complete analysis for HNSPF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
